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Abstract
Inflammation has been implicated as a perpetrator of diabetes and its associated complica-
tions. Monocytes, key mediators of inflammation, differentiate into pro-inflammatory M1
macrophages and anti-inflammatory M2 macrophages upon infiltration of damaged tissue.
However, the inflammatory cell types, which propagate diabetes progression and conse-
quential adverse disorders, remain unclear. The current study was undertaken to assess
monocyte infiltration and the role of fibroblast growth factor-9 (FGF-9) on monocyte to mac-
rophage differentiation and cardioprotection in the diabetic infarcted heart. Db/db diabetic
mice were assigned to sham, myocardial infarction (MI), and MI+FGF-9 groups. MI was in-
duced by permanent coronary artery ligation and animals were subjected to 2D transthorac-
ic echocardiography two weeks post-surgery. Immunohistochemical and immunoassay
results from heart samples collected suggest significantly increased infiltration of mono-
cytes (Mean ± SEM; MI: 2.02% ± 0.23% vs. Sham 0.75% ± 0.07%; p<0.05) and associated
pro-inflammatory cytokines (TNF-α, MCP-1, and IL-6), adverse cardiac remodeling (Mean ±
SEM; MI: 33% ± 3.04% vs. Sham 2.2% ± 0.33%; p<0.05), and left ventricular dysfunction
(Mean ± SEM; MI: 35.4% ± 1.25% vs. Sham 49.19% ± 1.07%; p<0.05) in the MI group. Im-
portantly, treatment of diabetic infarcted myocardium with FGF-9 resulted in significantly de-
creased monocyte infiltration (Mean ± SEM; MI+FGF-9: 1.39% ± 0.1% vs. MI: 2.02% ±
0.23%; p<0.05), increased M2 macrophage differentiation (Mean ± SEM; MI+FGF-9:
4.82% ± 0.86% vs. MI: 0.85% ± 0.3%; p<0.05) and associated anti-inflammatory cytokines
(IL-10 and IL-1RA), reduced adverse remodeling (Mean ± SEM; MI+FGF-9: 11.59% ± 1.2%
vs. MI: 33% ± 3.04%; p<0.05), and improved cardiac function (Fractional shortening,
Mean ± SEM; MI+FGF-9: 41.51% ± 1.68% vs. MI: 35.4% ± 1.25%; p<0.05). In conclusion,
our data suggest FGF-9 possesses novel therapeutic potential in its ability to mediate
monocyte to M2 differentiation and confer cardiac protection in the post-MI diabetic heart.
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Introduction
Diabetes mellitus is a metabolic disorder, which is characterized by hyperglycemia consequent
to the body’s inability to either produce any or sufficient quantities of insulin. Diabetic patients,
with chronic uncontrolled glycemic indexes, are at a higher risk for developing secondary dis-
orders including cardiovascular disease, retinopathy, nephropathy, and neuropathy [1–4].
Data suggest inflammation plays a critical role in the development and progression of diabetes
and associated complications through infiltration of immune cells and upregulated monocytic
activity [5–8].
Monocytes are key mediators of inflammation and upon infiltration into damaged tissue,
undergo reprogramming yielding two distinct macrophage phenotypes: pro-inflammatory M1
macrophages, which promote cytotoxic effects through secretion of inflammatory cytokines in-
cluding TNF-α, MCP-1, and IL-6 and anti-inflammatory M2 macrophages, which are impli-
cated in the mediation and resolution of inflammation, in part, through secretion of anti-
inflammatory cytokines including IL-10 and IL-1RA [9]. The ratio of M1:M2 macrophages has
been identified as a key determinant of the severity and progression of inflammatory propagat-
ed pathologies [10, 11]. In fact, several investigations using obese, insulin resistant db/db dia-
betic mice, have shown dysregulated monocyte/macrophage infiltration and retention with
subsequent enhanced pro-inflammatory cytokine release in the aorta and pancreatic islets and
during wound healing [5–8]. However, whether monocytic infiltration and M1/M2 macro-
phage differentiation outcomes play a role in adverse cardiac remodeling following MI in the
diabetic heart has yet to be evaluated and remains largely unknown.
FGFs comprise a family of twenty-two polypeptide growth factors that span a myriad of bio-
logical functions including those involved in embryonic development, tissue morphogenesis,
and post-natal physiological homeostasis [12, 13]. Specifically, FGF-9, initially isolated and
identified in culture media obtained from glial cells, has been shown to play an important role,
like other FGF family members, in variegated cellular processes, spanning multiple cell types
and tissues [14]. Such functions include neuronal cell growth and development, inner ear mor-
phogenesis, wound induced hair follicle neogenesis, joint development, neovasculogenesis, and
testicular embryogenesis [15–20]. Recently, data has been presented suggesting conditional ex-
pression of FGF-9 in the post-MI heart promoted vascularization and left ventricular hypertro-
phy, improved systolic function, and reduced subsequent death [21]. However, whether FGF-9
promotes cardioprotection in the post-MI diabetic heart through promotion of anti-inflamma-
tory mechanisms (enhanced M2 macrophage differentiation and anti-inflammatory cytokine
release) and diminished pro-inflammatory responses (reduced M1 macrophage differentiation
and pro-inflammatory cytokine secretion) remained elusive. The current study was undertaken
to evaluate the potential role of FGF-9 in directing monocyte to M2 macrophage differentiation
and its associated inhibition of adverse cardiac remodeling in the post-MI diabetic heart.
Materials and Methods
Coronary Artery Ligation and FGF-9 Treatment
All animal protocols were reviewed and approved by the University of Central Florida Institu-
tional Animal Care and Use Committee (IACUC). Male and female db/db diabetic mice, 8–10
weeks old were divided into 3 groups (n = 7–9 animals/group): Sham, MI, and MI+FGF-9
(1ng/10μl 0.1% BSA in 1X PBS). As previously detailed, mice were anesthetized using endo-tra-
cheal delivered isoflurane and subjected to a left thoracotomy [22, 23]. The left anterior de-
scending coronary artery was permanently ligated using a 7.0 polypropylene suture in the MI
and MI+FGF-9 groups. The sham-operated group was subjected to all procedures excluding
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policies and criteria.
permanent coronary artery ligation. Following ligation, the MI+FGF-9 group was injected with
FGF-9 into two independent sites (1 ng FGF-9/injection prepared as aforementioned for a total
dose of 2 ng FGF-9) in the peri-infarct region using a 29-guage floating needle. Two weeks
post-surgery, animals were sacrificed using 4% inhalatory isoflurane for 10 mins followed by
cervical dislocation. Hearts from all groups were removed, washed in phosphate buffered saline
(PBS), and preserved in either RNA later or formalin solution for future evaluations.
Tissue Section Preparation and Histopathology
Formalin preserved hearts were embedded in paraffin, cut into 5 μm serial sections, and placed
on Colorfrost plus-plus slides as previously published [24]. Following deparaffinization and re-
hydration, sections were stained with Masson’s Trichrome to visualize fibrosis (blue area). In-
farct size (%) was quantified by measuring (infarct area (mm2)/total area (mm2))100.
Interstitial fibrosis (IF) was quantified by evaluating the total blue area per mm2 with NIH
Image J software. Infarct size (%) and interstitial fibrosis were measured in 1–2 sections (4 im-
ages captured per section and calculated data averaged per section) from different animals. The
number of animals/group are listed in the figure legends.
Immunohistochemistry—Monocyte and Macrophage Identification
Sections were subjected to heat-induced epitope retrieval (HIER) for 20 mins followed by
blocking with 10% normal goat serum (Vector Labs) for one hr. Slides were incubated with pri-
mary anti-rabbit antibodies either against CD14 (monocytes, Abbiotec, #25156, 1:50), iNOS
(M1 macrophages, Abcam, #ab129372, 1:50), or CD206 (M2 macrophages, Abcam, #ab64693,
1:50) overnight at 4°C. Slides were then washed and incubated with appropriate secondary an-
tibodies for one hr at room temperature. All slides were additionally double stained with pri-
mary (and appropriate secondary) antibodies against sarcomeric α-actin (Src α-actin) (cardiac
myocyte, Sigma, #A2172, 1:30). Src α-actin staining was carried out using M.O.M. Immunode-
tection kit reagents following the Multiple Immunofluorescent Labeling protocol provided
(Vector Laboratories, #FMK-2201). Sections were counter stained with mounting medium
containing DAPI (4’, 6-diamidino-2-phenylindole) (Vector Labs) and cover-slipped. Four im-
ages per section (1–2 sections, n = 5 animals/group) were taken for data quantification using
an Olympic IX-70 fluorescent microscope and representative images were captured using a
confocal microscope. Cells positive for CD14, iNOS, or CD206 were independently counted,
divided by the total number of nuclei, and expressed as a percent of positive cells/section.
Real-time RT-PCR
Total RNA was prepared from heart homogenates according to the manufacturer’s instructions
using TRI Reagent RNA Isolation Reagent (Sigma-Aldrich). RNA was reversely transcribed
using iScript Select cDNA Synthesis Kit (Bio-Rad) with Random primers, and real-time PCR
was carried out using a C1000 Thermal Cycler (Bio-Rad). Real-time PCR analysis was per-
formed using SYBR Green (Bio-Rad) and normalized to GAPDH. Relative expression was as-
sessed by the comparative CT method correcting for amplification efficiency of the primers.
Primers used for real-time PCR were as follows:
TNFα: sense primer, 50-CACAGAAAGCATGATCCGCGACGT-30;
Antisense primer, 50-CGGCAGAGAGGAGGTTGACTTTCT-30;
IL-6: sense primer, 50-TCCAGTTGCCTTCTTGGGAC-30;
Antisense primer, 50-GTACTCCAGAAGACCAGAGG-30;
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IL-10: sense primer, 50-TGGCCCAGAAATCAAGGAGC-30;
Antisense primer, 50-CAGCAGACTCAATACACACT-30;
GAPDH: sense primer, 50-AACGACCCCTTCATTGAC-30;
Antisense primer, 50-TCCACGACATACTCAGCAC-30;
Arg1: sense primer, 50-CTCCAAGCCAAAGTCCTTAGAG-30;
Antisense primer, 50-AGGAGCTGTCATTAGGGACATC-30;
Data is presented as relative fold increase against the sham group.
Pro- and Anti-Inflammatory Cytokine Analysis by ELISA
Secreted pro-inflammatory cytokines (TNF-α#ELM-TNFalpha-001, #MCP-1 #ELM-MCP-
001, and IL-6 #ELM-IL6-001) and anti-inflammatory cytokines (IL-10 #ELM-IL10-001 and
IL-1RA #ELM-IL1RA-001) were quantified using commercially available RayBiotech ELISA
kits. In brief, heart tissue was homogenized in RIPA buffer containing PMSF, sodium ortho-
vandate, and sodium fluoride. Following centrifugation, supernatant was collected and protein
concentration was quantified using the Bradford assay. All ELISAs were performed following
manufacturer’s instructions and the resulting colorimetric reactions were measured at 450 nm.
Results were normalized to protein concentration and data is presented as pg/ml.
Cardiac Function Analysis
Two weeks post-sham or MI surgery, transthoracic 2D echocardiography was performed using
the 5500 Ultrasound System as previously described [25]. A 15-6L hockey stick transducer was
used to capture M-mode images of the left ventricle for left ventricular internal dimension-di-
astole (LVIDd), left ventricular internal dimension-systole (LVIDs), fractional shortening (FS,
((LVIDd-LVIDs)/LVIDd x 100)), left ventricular volume at end diastole (EDV), left ventricular
volume at end systole (ESV), and ejection fraction (EF, ((EDV-ESV)/EDV x 100)) calculations.
Statistical Analysis
Statistical analysis of data was performed using one-way analysis of variance (ANOVA) fol-
lowed by the Tukey Test. Data is presented as a mean ± SEM with p<0.05 considered
statistically significant.
Results
Infarct Size and Fibrosis Blunted Following FGF-9 Treatment in Post-MI
Diabetic Myocardium
To determine the effects of FGF-9 on infarct size and interstitial fibrosis in the post-MI diabetic
heart, Masson’s trichrome staining was performed on heart sections from all study groups.
Representative images depicting infarct are shown in Fig. 1A-C and interstitial fibrosis in
Fig. 1D-F. Quantitative analysis revealed a significant increase in infarcted myocardium in the
MI group relative to the sham-operated group (p<0.05, Fig. 1G). However, when administered
FGF-9 post-MI, infarct size was significantly abrogated compared to the MI group (p<0.05,
Fig. 1G). Interstitial fibrosis, quantified in the left ventricular myocardium by direct measure-
ment of the blue area using Image J software, was significantly elevated in the MI group relative
to the sham group (p<0.05, Fig. 1H). Markedly, the interstitial fibrotic region was significantly
reduced following FGF-9 treatment (p<0.05, Fig. 1H). Collectively, our data suggest that
FGF-9 Enhances M2 Macrophage Differentiation
PLOS ONE | DOI:10.1371/journal.pone.0120739 March 13, 2015 4 / 13
treatment with FGF-9 minimizes infarct size as well as blunts fibrosis formation in the post-MI
diabetic myocardium.
Monocyte Infiltration in Post-MI Diabetic Heart is Abrogated Following
FGF-9 Treatment
To extrapolate mechanisms by which FGF-9 protects endogenous myocardial architecture
post-MI, inflammatory cells, specifically monocytes, were quantified. Fig. 2A-O contains repre-
sentative photomicrographs of heart sections stained with CD14, a marker for monocytes, in
red (A, F, and K), sarcomeric α-actin for cardiac myocytes in green (B, G, and L), DAPI for nu-
clei in blue (C, H, and M), merged images (D, I, and N), and enhanced merged images (E, J,
and O). Quantitative analysis suggests a significant upregulation of infiltrated monocytes fol-
lowing MI relative to the sham group (p<0.05, Fig. 2P). Conversely, monocyte infiltration was
significantly reduced upon FGF-9 treatment compared to the MI group (p<0.05, Fig. 2P).
M1Macrophage Differentiation is Diminished Following FGF-9
Treatment in the Post-MI Diabetic Heart
To evaluate monocytic reprogramming outcomes post-infiltration into the infarcted myocardi-
um, we quantified differentiated pro-inflammatory M1 and anti-inflammatory M2
Fig 1. FGF-9 Inhibits Infarct and Fibrosis in the Post-MI Diabetic Myocardium. A-F: Representative images of Masson’s trichrome stained sections are
shown depicting infarct (A-C) and interstitial fibrosis (D-F) for control and experimental groups 2 weeks post-MI. Single arrows represent infarcted
myocardium. Double arrows represent interstitial fibrosis.G: Histogram of quantitative infarct size analysis suggests a significant decrease in infarct size in
the MI+FGF-9 group compared to the MI group.H: Histogram of mean left ventricular cardiac myocyte cross sectional interstitial fibrotic (IF) area (mm2).
n = 5–8 animals/group. *p<0.05 vs. sham and #p<0.05 vs. MI.
doi:10.1371/journal.pone.0120739.g001
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macrophages. To demonstrate M1 macrophages, representative photomicrographs are shown
in Fig. 3A-O depicting iNOS positive M1 macrophages in red (A, F, and K), cardiac myocytes
in green (B, G, and L), total nuclei in blue (C, H, and M), merged images (D, I, and N), and en-
hanced merged images (E, J, and O) for all control and experimental groups. The number of
iNOS positive M1 macrophages was significantly enhanced post-MI compared to sham con-
trols (p<0.05, Fig. 3P). However, the number of M1 macrophages was significantly decreased
in the FGF-9 treated mice relative to the MI group (p<0.05, Fig. 3P).
Data suggest macrophage subtypes have distinct cytokine profiles with M1 macrophages
contributing to enhanced pro-inflammatory TNF-α and IL-6 secretion, to name a few [26]. In
this regard, mRNA levels of TNF-α and IL-6 were evaluated by RT-PCR to identify a correla-
tion between enhanced M1 macrophage differentiation and pro-inflammatory cytokine expres-
sion in the diabetic infarcted myocardium. Transcribed levels of TNF-α and IL-6 were
significantly elevated in the post-MI heart relative to sham control animals (p<0.05, Fig. 3Q
and R, respectively). Notably, post-MI administration of FGF-9 significantly blunted both
TNF-α and IL-6 mRNA levels compared to the MI group (p<0.05, Fig. 3Q and R,
respectively).
M2Macrophage Differentiation is Enhanced in the Post-MI Diabetic
Heart Following FGF-9 Treatment
Representative images of heart sections shown in Fig. 4A-O depict CD206 positive M2 macro-
phages in red (A, F, and K), cardiac myocytes in green (B, G, and L), total nuclei in blue (C, H,
and M), merged images (D, I, and N), and enhanced merged images (E, J, and O). Although
not statistically significant, a decrease in M2 macrophage populations was observed in the MI
group relative to the sham group (Fig. 4P). Importantly, results showed significantly elevated
M2 macrophage concentrations in MI+FGF-9 hearts relative to sham and MI groups, suggest-
ing FGF-9 may play a role in monocyte to M2 macrophage differentiation (p<0.05, Fig. 4P).
Furthermore, mRNA expression of IL-10, an anti-inflammatory cytokine produced by
Fig 2. FGF-9 Blunts Monocyte Infiltration in Infarcted Diabetic Myocardium. A-O: Representative photomicrographs illustrate CD14 positive monocytes
in red (A, F, andK), cardiac myocytes in green (B,G, and L), total nuclei in blue (C, H, andM), merged images (D, I, andN), and enhanced merged images
(E, J, andO) for all control and experimental groups. White arrows are used to show the areas enhanced inD, I, andN. Scale bar = 75μm. P: Histogram of
quantitative monocyte infiltration data 2 weeks post-MI. n = 5 animals/group. *p<0.05 vs. sham and #p<0.05 vs. MI.
doi:10.1371/journal.pone.0120739.g002
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alternatively activated M2 macrophages, was significantly upregulated in the MI+FGF-9 group
relative to the MI group (p<0.05, Fig. 4Q) [26].
Treatment with FGF-9 Decreases Pro-Inflammatory Cytokine
Expression
Next, we evaluated the effects of FGF-9 treatment on translated pro-inflammatory cytokine ex-
pression, including TNF-α, MCP-1, and IL-6. Quantification of TNF-α expression via a TNF-
α ELISA indicated significantly escalated TNF-α levels in the MI group relative to sham con-
trols (p<0.05, Fig. 5A). However, treatment with FGF-9 attenuated levels of TNF-α compared
to the MI group (p<0.05, Fig. 5A). Results from the MCP-1 ELISA indicated increased levels
of MCP-1 in the MI group as compared to the sham group (p<0.05, Fig. 5B). Conversely, the
MI+FGF-9 group had significantly decreased MCP-1 expression compared to the MI group
Fig 3. Monocyte to M1 Macrophage Polarization is Blunted Following FGF-9 Treatment. A-O: Representative photomicrographs demonstrate iNOS
positive M1 macrophages in red (A, F, andK), cardiac myocytes in green (B,G, and L), total nuclei in blue (C, H, andM), merged images (D, I, andN), and
enhanced merged images (E, J, andO) for all control and experimental groups. White arrows are used to show the areas enhanced in D, I, andN. Scale
bar = 75μm. P: 2 weeks post-MI, M1 macrophage popoluations are significantly decreased in the MI+FGF-9 group. n = 5 animals/group.Q: Pro-inflammatory
TNF-αmRNA expression was evaluated by RT-PCR and data provided suggest a significant increase post-MI.R: Proinflammatory IL-6 mRNA expression
was significantly decreased following FGF-9 treatement in the post-MI diabetic heart. *p<0.05 vs. sham and #p<0.05 vs. MI.
doi:10.1371/journal.pone.0120739.g003
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(p<0.05, Fig. 5B). Additionally, levels of IL-6 were assessed and quantitative analysis of MI
tissues showed up-regulated IL-6 levels compared to sham, whereas the MI+FGF-9 group
had significantly down-regulated IL-6 expression relative to expression levels in the MI
group (p<0.05, Fig. 5C). Our data collectively suggest that FGF-9 promotes cardioprotection
post-MI through mechanisms that contribute to down-regulated pro-inflammatory cytokine
expression.
Anti-Inflammatory Cytokine Expression Increases Following FGF-9
Treatment in the Post-MI Diabetic Heart
Reported previously, M2 macrophages secrete anti-inflammatory cytokines [27, 28]. In this re-
gard, levels of IL-10 and interleukin-1 receptor antagonist (IL-1RA), critical mediators of in-
flammation and immunoregulation, were assessed. Following treatment with FGF-9, a
significant increase in IL-10 was observed compared to sham and MI groups (p<0.05, Fig. 5D).
Additionally, levels of IL-1RA were significantly increased in the MI+FGF-9 group compared
to the sham and MI groups (p<0.05, Fig. 5E). Collectively, our data suggest FGF-9 promotes
M2 macrophage differentiation and subsequent anti-inflammatory expression.
Fig 4. M2 Macrophages are Significantly Enhanced Following FGF-9 Treatment. A-O: Representative photomicrographs demonstrate CD206 positive
M2 macrophages in red (A, F, andK), cardiac myocytes in green (B,G, and L), total nuclei in blue (C, H, andM), merged images (D, I, andN), and enhanced
merged images (E, J, andO) for all control and experimental groups. White arrows are used to show the areas enhanced in D, I, andN. Scale bar = 75μm. P:
Quantitative data suggest that M2 macrophage concentrations are significantly greater in the MI+FGF-9 group relative to sham and MI groups. n = 5
animals/group.Q: Anti-inflammatory IL-10 mRNA expression, evaluated by RT-PCR, was significantly upregulated post-FGF-9 treatment. *p<0.05 vs. sham
and #p<0.05 vs. MI.
doi:10.1371/journal.pone.0120739.g004
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Exogenous FGF-9 Improves Cardiac Function in Post-MI Diabetic Mice
To determine the impact of FGF-9 on left ventricular function post-MI, 2D transthoracic echo-
cardiography was performed on all control and experimental mice. All raw data is provided in
Fig. 6A. Two weeks post-MI, EDV and ESV were significantly increased (p<0.05, Fig. 6E and
F, resepctively), whereas FS and EF were significantly diminished compared to the sham oper-
ated mice (p<0.05, Fig. 6D and G, resepctively). Notably, LVIDd, LVIDs, EDV, and ESV were
significantly decreased (p<0.05, Fig. 6B, C, E, and F, resepctively) and FS amd EF were signifi-
cantly improved (p<0.05, Fig. 6D and G, resepctively) in the FGF-9 treated mice relative to the
MI alone mice. All echocardiographic data, taken into consideration, suggest FGF-9 preserves
systolic and diastolic function and protects the diabetic heart from cardiac dysfunction conse-
quent to MI.
Discussion
Myocardial infarction (MI) is associated with an inflammatory response, which precedes and
promotes adverse cardiac remodeling in an attempt to rescue endogenous myocardial architec-
ture with consequential loss of normal left ventricular function [29, 30]. Monocytes are key me-
diators in the development and progression of inflammation as they migrate to the damaged
area and differentiate into various cell types, including macrophages. Monocyte to macrophage
differentiation and/or polarization yields two distinct macrophage populations: “classically ac-
tivated” M1 pro-inflammatory macrophages and “alternatively activated” M2 anti-inflamma-
tory macrophages [31]. Notably, several clinical studies have suggested the presence of elevated
monocytic activity and pro-inflammatory cytokine expression, including TNF-α and IL-6, in
the blood circulation of diabetic patients [32–34]. However, no studies have been carried out to
Fig 5. FGF-9 Treatment Augments Pro- and Anti-Inflammatory Cytokine Secretion. 2 weeks following MI, heart homogenates were used to quantify pro-
and anti-inflammatory cytokine secretion via ELISA analysis. Pro-inflammatory cytokine expression, including that of TNF-α, MCP-1, and IL-6, are shown in
A, B, and C, respectively whereas anti-inflammatory IL-10 and IL-1RA cytokine expression are depicted inD and E, respectively. n = 5 animals/group.
*p<0.05 vs. sham and #p<0.05 vs. MI.
doi:10.1371/journal.pone.0120739.g005
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examine monocyte infiltration in the diabetic post-MI heart, nor has any attempt been made to
control monocyte to macrophage polarization and differentiation. Within the present study, our
data, for the first time as per the best of our knowledge, will show that two weeks post-MI, there
was a significant increase in infiltrated monocytes and enhanced pro-inflammatory cytokine ex-
pression in the diabetic heart. Importantly, we reported that treatment with FGF-9 1) reduced in-
farct size and interstitial fibrosis, 2) reduced myocardial monocyte infiltration, 3) significantly
decreased M1 macrophage populations and pro-inflammatory cytokine expression, 4) enhanced
M2 macrophage populations and anti-inflammatory cytokine secretion, and 5) improved cardiac
function. Our data suggest FGF-9 is a novel mediator of monocyte/macrophage phenotype plas-
ticity in the infarcted diabetic myocardium and may have therapeutic potential, with respect to a
decreased inflammatory response, for the prevention of post-MI adverse remodeling.
Following MI and subsequent loss of cardiac cell types via apoptosis and necrosis, reparative
processes, including fibrosis formation, are triggered to rebuild and restore infarcted tissue
and maintain the architectural integrity of the myocardium [22]. Albeit necessary, fibrosis
leads to an infacrt scar which lacks contractile capabilities with consequential loss of normal
Fig 6. Exogenous FGF-9 Treatment Improves Cardiac Function Following MI. 2 weeks post MI, 2D transthoracic echocardiography was performed on
control and experimental animals. All mean data for each quantified measurement are presented in A. Quantitative analyses are shown for left ventricular
internal dimension-diastole (LVIDd) (B), left ventricular internal dimension-systole (LVIDs) (C), fractional shortening (FS) (D), left ventricular volume at end
diastole (EDV) (E), left ventricular volume at end systole (ESV) (F), and ejection fraction (EF) (G). n = 5 animals/group. *p<0.05 vs. sham and #p<0.05 vs.
MI.
doi:10.1371/journal.pone.0120739.g006
FGF-9 Enhances M2 Macrophage Differentiation
PLOS ONE | DOI:10.1371/journal.pone.0120739 March 13, 2015 10 / 13
left ventricular funcion. Two weeks following permenant coronory artery ligation, infarcted
myocardium comprised more than 30% of the total area measured with coexistent interstital fi-
brosis significantly elevated. Cardiac myocytes in the infacrted myocardium appeared dystro-
phic, enlarged, and hypertropic in nature compared to those in sham operated animals.
Treatment with ex vivo FGF-9 significantly reduced the infarcted and interstital fibrotic area.
Concurrent with our findings, Korf-Klingebiel et al. reported a significant decrease in intersti-
tial fibrosis post-MI in cardiac-specific FGF-9 expressing transgenic mice [21].
During the initial MI-induced inflammatory response, neutrophils accumulate in the infarcted
myocardium [35]. Thereafter, the myocardial filtrate is mainly comprised of monocytes and their
macrophage descendants [36]. Consistent with these previous published data, monocytic infiltra-
tion was significantly increased in hearts of diabetic MI mice, as evidenced by CD14 staining.
However, when additionally treated with FGF-9, monocyte infiltration was dramatically reduced.
Such findings are unique in that no study has previously reported FGF-9 to play a role in the in-
flammatory response following MI by inhibiting the infiltration of cardiac monocytic populations.
Accruing evidence suggest that not only is monocyte infiltration a determinant of inflam-
mation severity and disease progression but also macrophage type yields following monocyte
differentiation [10, 11, 31, 36]. Specifically, studies have shown that M1 macrophages, signifi-
cantly outnumbering M2 subtypes during pathological inflammation, initiate and sustain in-
flammation whereas M2 macrophages promote reparative processes to resolve and quench
chronic inflammation [27, 35, 37]. Consistent with these investigations, M1 macrophage popu-
lations were dramatically increased with significant upregulation in secreted pro-inflammatory
cytokines and M2 macrophage polarization and anti-inflammatory cytokine expression was
blunted following MI surgery in diabetic mice. Conversely, following FGF-9 treatment, mono-
cyte to M1 macrophage polarization and secreted TNF-α, MCP-1, and IL-6 were significantly
reduced whereas M2 polarization and anti-inflammatory IL-10 and IL-1RA expression were
dramatically enhanced. Data presented suggest FGF-9 protected the diabetic heart from post-
MI remodeling by directing the differentiation of monocytes into M2 macrophages and ulti-
mately minimizing the adverse endogenous inflammatory response.
Finally, we needed to determine the effects of FGF-9 treatment post-MI on overall cardiac
function. FGF-9 treatment significantly improved left ventricular function as evidenced by en-
hanced EF and FS relative to the MI group. Albeit mechanisms leading to improved cardiac
function are complex, our data suggest that FGF-9 may provide cardioprotection, structurally
and functionally, by driving monocyte to M2 macrophage differentiation, thus minimizing ad-
verse inflammatory-induced cardiac remodeling in the diabetic heart.
In conclusion, our data show, for the first time, that the diabetic infarcted myocardium is in-
filtrated with monocytes and differentiated M1 macrophages with enhanced pro-inflammatory
cytokine secretion observed. Remarkably, treatment with FGF-9 significantly decreased infil-
trated monocyte concentrations, M1 macrophage differentiation, and pro-inflammatory cyto-
kine secretion. Furthermore, FGF-9 treatment increased M2 macrophage differentiation as
well as the secretion of anti-inflammatory mediators ultimately protecting the infarcted diabet-
ic myocardium from adverse cardiac remodeling and improving cardiac function. Collectively,
our data suggest that FGF-9 directs monocyte differentiation and has cardioprotective potential
in the post-MI diabetic heart.
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